Peripheral T-Cell Lymphoma Genome Cracked Open

Researchers at the Mayo Clinic in Rochester have completed the first known genome-wide analysis of peripheral T-cell lymphomas (PTCL).

According to their research, published in Blood, the journal of the American Society of Hematology, and titled, "Genome-wide Analysis Reveals Recurrent Structural Abnormalities of TP63 and other p53-related Genes in Peripheral T-cell Lymphomas" a number of genomic abnormalities have been discovered that should help researchers develop more targeted therapies against PTCLs, such as:

  • PTCLs feature at least 13 chromosomal rearrangements
  • Five of them involve p53 genes
  • Two newly uncovered ones, TP53 and TP63, indicate a poorer prognosis

T-cell lymphomas are underclassified

This is good news for in the world of T-cell lymphomas. Long the poorly understood and widely ignored step-child to lymphomas of B-cell origin, T-cell lymphomas in general have a poorer prognosis than B-cell lymphomas, and remain extremely under-classified.

In fact, while there are a handful of PTCL subtype classifications, more often than not the diagnosis for many patients is PTCL-NOS, or peripheral T-cell lymphoma not otherwise specified, a classification that Mayo researcher Andrew Feldman refers to as a "wastebasket diagnosis" because it includes so many variations that remain poorly understood, if understood at all.

One of the hopes from having carried out the first genome-wide look at PTCLs is that not only will it lead to better therapies, but that accuracy in diagnosis will improve. While accurate diagnoses of most cancers, including B-cell lymphomas, can be made by most pathologists, T-cell lymphomas are so difficult to diagnose that second opinions ought to be mandatory, and they should always be made by a certified blood pathologist.

"Every time I diagnose a peripheral T-cell lymphoma, I know that two out of three patients will succumb to that lymphoma," said Feldman. "That's a very unsatisfying feeling, and I hope that our research can help change those statistics."

Source: Mayo Clinic

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap